Cargando…

Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients

BACKGROUND: MicroRNAs are a family of 19- to 25-nucleotides noncoding small RNAs that primarily function as gene regulators. Aberrant microRNA expression has been described for several human malignancies, and this new class of small regulatory RNAs has both oncogenic and tumor suppressor functions....

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Masami, Oikawa, Kosuke, Takanashi, Masakatsu, Kudo, Motoshige, Ohyashiki, Junko, Ohyashiki, Kazuma, Kuroda, Masahiko
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678255/ https://www.ncbi.nlm.nih.gov/pubmed/19440243 http://dx.doi.org/10.1371/journal.pone.0005532

Ejemplares similares

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
por: Ohyashiki, Junko H, et al.
Publicado: (2010)

Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma
por: Ohyashiki, Kazuma, et al.
Publicado: (2011)

Age-related decrease of miRNA-92a levels in human CD8(+ )T-cells correlates with a reduction of naïve T lymphocytes
por: Ohyashiki, Michiyo, et al.
Publicado: (2011)

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders
por: Yoshizawa, S, et al.
Publicado: (2012)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
por: Ohyashiki, Kazuma, et al.
Publicado: (2016)

Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15
por: Nishi, Hirotaka, et al.
Publicado: (2023)

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells
por: Ohyashiki, Junko H, et al.
Publicado: (2008)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

MORPHOLOGIC CHANGES OF NEUTROPHILS IN MYELODYSPLASTIC SYNDROME TREATED WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR
por: Toyama, Keisuke, et al.
Publicado: (1988)

Non‐radioisotopic and Semi‐quantitative Procedure for Terminal Repeat Amplification Protocol
por: Ohyashiki, Junko H., et al.
Publicado: (1996)

Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
por: Ohyashiki, Kazuma, et al.
Publicado: (1989)

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
por: Ohyashiki, Junko H, et al.
Publicado: (2014)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
por: Yoshimoto, Takayuki, et al.
Publicado: (2014)

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
por: Ohyashiki, Junko H, et al.
Publicado: (2012)

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells
por: Imanishi, Satoshi, et al.
Publicado: (2018)

Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis
por: Gladkova, Nina, et al.
Publicado: (2020)

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2015)

Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation
por: Yoshizawa, Seiichiro, et al.
Publicado: (2018)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma
por: Katagiri, Seiichiro, et al.
Publicado: (2017)

Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2018)

Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment
por: Tanaka, Yuko, et al.
Publicado: (2022)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome
por: Asano, Michiyo, et al.
Publicado: (2019)

Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2017)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
por: Okabe, Seiichi, et al.
Publicado: (2015)

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2016)

Anthocyanidins-enriched bilberry extracts inhibit 3T3-L1 adipocyte differentiation via the insulin pathway
por: Suzuki, Rieko, et al.
Publicado: (2011)

Transcriptional profiling of Epstein–Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection
por: Zhang, Y, et al.
Publicado: (2006)

Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis
por: Yamada, Yuko, et al.
Publicado: (2017)

WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7
por: Kumagai, Katsuyoshi, et al.
Publicado: (2021)

Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells
por: Hamamura, R S, et al.
Publicado: (2007)

Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells
por: Ohyashiki, J H, et al.
Publicado: (2005)

miR-17–92 cluster: ups and downs in cancer and aging
por: Grillari, Johannes, et al.
Publicado: (2010)

Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
por: Elhamamsy, Amr Rafat, et al.
Publicado: (2017)

An improved Red/ET recombineering system and mouse ES cells culture conditions for the generation of targeted mutant mice
por: Kumagai, Katsuyoshi, et al.
Publicado: (2016)

Cisplatin induces differentiation in teratomas derived from pluripotent stem cells
por: Kurata, Atsushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ma6p7a3o4apmcesk3phbufcjlu